Voyager Therapeutics’ (VYGR) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a $30.00 price target on the stock.

Several other analysts have also commented on the stock. Leerink Partners started coverage on shares of Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target on the stock. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research report on Sunday, November 10th. Finally, Wedbush lowered their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Voyager Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Voyager Therapeutics Trading Down 9.3 %

Shares of VYGR opened at $5.64 on Thursday. The firm’s 50-day moving average is $6.62 and its two-hundred day moving average is $7.50. Voyager Therapeutics has a twelve month low of $5.59 and a twelve month high of $11.72. The firm has a market capitalization of $308.11 million, a P/E ratio of 7.94 and a beta of 0.89.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. During the same period in the prior year, the business posted ($0.59) earnings per share. Analysts predict that Voyager Therapeutics will post -1.2 EPS for the current year.

Insiders Place Their Bets

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the transaction, the insider now owns 86,001 shares of the company’s stock, valued at $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 4.53% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds have recently made changes to their positions in VYGR. Ameritas Investment Partners Inc. raised its stake in shares of Voyager Therapeutics by 49.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock valued at $37,000 after acquiring an additional 1,300 shares during the period. Plato Investment Management Ltd purchased a new position in shares of Voyager Therapeutics in the 1st quarter valued at $38,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Voyager Therapeutics by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after acquiring an additional 4,098 shares during the period. Intech Investment Management LLC purchased a new position in shares of Voyager Therapeutics in the 3rd quarter valued at $74,000. Finally, SG Americas Securities LLC purchased a new position in shares of Voyager Therapeutics in the 2nd quarter valued at $85,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.